EDVA Endovia Health Sciences, Inc.
Beverages · NYSE · SEC CIK 1553788 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY79.3%
TTM net income YoY33.3%
TTM EPS YoY89.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-13.6%
Operating margin3,741.9%
Net margin4,787.7%
FCF margin—
EBITDA margin3,756.9%
Returns
ROE—
ROA-148.3%
ROIC (approx.)—
Asset turnover-0.03x
Leverage & solvency
Liabilities / assets1,563.2%
Debt / equity—
Current ratio0.05x
Interest coverage-5.67x
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-101.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $73,066 | $801,273 |
| Cost of revenue | — | $3.80M |
| Gross profit | $16,898 | -$119,797 |
| Operating income | -$14.19M | -$9.90M |
| Interest expense | $2.52M | $3.70M |
| Income tax | $0 | $0 |
| Net income | -$25.23M | -$23.76M |
| EBITDA | -$14.18M | -$9.50M |
| EPS (basic) | -11.97 | -17.68 |
| EPS (diluted) | -11.97 | -17.68 |
| Weighted avg. shares (diluted) | 2.18M | 1.34M |
| Banking | ||
| Net interest income | -$2.52M | -$3.70M |
| Balance sheet | ||
| Cash & equivalents | $281,435 | $15,346 |
| Receivables | $15,748 | $191,991 |
| Inventory | $33,538 | $319,104 |
| Current assets | $631,993 | $1.90M |
| PP&E, net | $12,926 | $22,210 |
| Total assets | $965,694 | $2.76M |
| Current liabilities | $16.26M | $19.37M |
| Long-term debt | $3,418 | $1.97M |
| Total debt | $3,418 | $1.97M |
| Total liabilities | $16.27M | $21.39M |
| Shareholders' equity | -$15.30M | -$18.63M |
| Net debt | -$278,017 | $1.96M |
| Shares outstanding | 749,450 | 1.67M |
| Cash flow statement | ||
| Operating cash flow | -$4.82M | -$7.30M |
| Capital expenditure | — | $3,235 |
| Free cash flow | — | -$7.31M |
| Investing cash flow | — | -$3,235 |
| Financing cash flow | $5.10M | $7.54M |
| Depreciation & amortization | $9,284 | $401,602 |
| Stock-based compensation | $8.62M | $2.36M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.